Enhanced immune effector cells and use thereof
AssigneeFate Therapeutics, Inc.
InventorsBahram VALAMEHR, Ryan BJORDAHL, Jode GOODRIDGE, Tom Tong LEE
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
Claims26
-29. (canceled)
A method of improving anti-CD38 antibody treatment comprising administering to a subject under the treatment effector cells without CD38 expression.
A method of reducing or preventing allorejection against allogenic effector cells by using a CD38 specific antagonist, wherein the allogenic effector cells comprise CD38 knockout, and wherein the CD38 specific antagonist is capable of suppressing activated T and B cells in a recipient of the allogenic effector cells.
Dependencies are inferred from the claim text.